Agent for potentiating the effect of interleukin-8

Details Agent for potentiating the effect of interleukin-8 Agent for potentiating the effect of interleukin-8

1998-10-14

2001-03-06

Mertz, Prema (Department: 1646)

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

C514S002600, C514S008100, C514S012200, C514S885000, C514S169000

Reexamination Certificate

active

06197291

ABSTRACT:

TECHNICAL FIELD
This invention relates to an agent for potentiating the effect of interleukin-8. In detail, the invention relates to an agent, which comprises dehydroepiandrosterone sulfate or a pharmaceutically acceptable salt thereof as an active ingredient, for potentiating the effect of interleukin-8.
BACKGROUND ART
Interleukin-8 (hereinafter referred to as IL-8) is a cytokine induced by monocytes, macrophages, fibroblasts, vascular endothelial cells, skin keratinized cells, renal mesangial cells, epithelial cells of intestine and respiratory tract, liver parenchyma cells and various tumor cells, and is known as a potent chemotactic factor affecting neutrophil, T-lymphocyte and basophil.
IL-8 has been reported to effectively influence the maturity of the uterine cervix in delivery and interrupted pregnancy (see WO93/09796), to have a therapeutic effect on allergic disease causing asthma, etc. by inhibiting histamine—releasing factor (HRF) from basophils (see WO92/01465), to have a therapeutic effect on Alzheimer disease and Huntington disease etc. by protective effects on the neuronal cell (see Chemical Abstracts Vol.119: 109015k), to be effective as an accelerating agent for healing wounds such as skin burns by accelerating the increase in vascular endothelial cell (see Chemical Abstracts Vol.119: 201760k) and so on. Furthermore, IL-8 is expected to develop an agent to target improvement of immunodeficiency, prevent opportunistic infection, promote anti-tumor effect, etc. by activating neutrophils and enhancing anti-bacterial effects [Zoketsu Inshi (Hematopoietic Factor), Vol.2, No.1, 46, 1991 and Med. Immunol., Vol.20, No.3, 305, 1990].
Dehydroepiandrosterone sulfate (hereinafter referred to as DHAS) or a pharmaceutically acceptable salt thereof improve the maturity of the uterine cervix and the sensitivity of uterine musculature to oxytocin in the late phase of pregnancy (see U.S. Pat. No. 4,005,200). The sodium salt performed well as an agent to improve the maturity of the uterine cervix. It is also well known that DHAS or a pharmaceutically acceptable salt thereof are effective as therapy for dementia (see U.S. Pat. No. 4,868,161), therapy and prevention of hyperlipemia (see GB2208473), therapy for osteoporosis (see U.S. Pat. No. 5,116,828) and therapy for ulcer (see Chemical Abstracts Vol. 122 142528q).
Furthermore, DHAS or a pharmaceutically acceptable salt thereof have been reported to increase the production of interleukin-2 and interleukin-4 (see WO91/04030), normalize the level of interleukin-6 induced abnormally by injury, aging and autoimmune disease (see WO93/21771).
However, neither DHAS or a pharmaceutically acceptable salt thereof has been reported to increase the effect of IL-8.
DISCLOSURE OF THE INVENTION
The inventors have now completed an invention by which DHAS or a pharmaceutically acceptable salt thereof increase the effect of IL-8 by activating both receptor, type I and type II of IL-8 receptor, and further by increasing the number of receptors.


REFERENCES:
patent: 3209328 (1991-09-01), None
patent: 6299328 (1997-05-01), None

Affiliated with

Also associated with

Rating

Agent for potentiating the effect of interleukin-8 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Agent for potentiating the effect of interleukin-8, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agent for potentiating the effect of interleukin-8 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2455494